Spear UltraDetect™ Assay Resources
Application Notes & Technical Notes
Successive Proximity Extension Amplification Reaction (SPEAR) and its Two-Factor Authentication Mechanism
Discover how this ultrasensitive immunoassay platform detects blood-based protein biomarkers of Alzheimer’s disease at fg/mL levels, enabling early prognosis, screening, and therapy monitoring.
Unlocking the Potential of pTau 231 in Alzheimer’s Disease Research with the Enhanced Sensitivity and Precision of the SPEAR UltraDetect™ pTau 231 Assay
See how the SPEAR UltraDetect™ pTau 231 Assay sets a new benchmark for one of the most promising plasma biomarkers for early Alzheimer’s detection.
Unparalleled Precision of SPEAR UltraDetect™ Immunoassays with Homogeneous Format: GFAP and NF-L
Discover how SPEAR UltraDetect™ NF-L and GFAP Assays can reveal neurological biomarker insights that other assays miss.
SPEAR UltraDetect™ Neurofilament Light Exceptional Precision with F.A.S.T.™ Automated Workflow
Explore how SPEAR technology delivers superior sensitivity and specificity in detecting Neurofilament Light (NF-L) compared to conventional immunoassays, enabling ultra-sensitive protein detection from sub-microliter serum or plasma samples.
Case Studies & Testimonials
From Precious Samples to Powerful Insights: How the SPEAR UltraDetect™ pTau 217 Assay Unlocks Greater Discrimination of Amyloid Positives Using 1 µL of Diluted Sample
Dr. Thomas Karikari, a leading researcher in Alzheimer’s blood-based biomarkers, presents results using the SPEAR UltraDetect™ pTau 217 Assay across two diverse cohorts. The SPEAR Assay consistently outperformed other assays in accuracy, sensitivity, and precision, even when working with archived samples that had undergone multiple freeze-thaw cycles.
